Teva Pharmaceuticals Australia Pty Ltd

Teva Pharmaceuticals Pty Ltd

Collette Behrens

Anthony Gerard Doyle

Sarah Lee Pogue

Adam Clarke

Matthew Pollard

David S Wilson

David S Wilson, Jr

Tetsuya Taura

Teresa Domagala

Tetsuo Yamagishi

David Wilson

Adam W Clarke

Anthony G Doyle

The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon &#x3b1; 2b (IFN&#x3b1;2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN&#x3b1;2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN&#x3b1;2b.

Interferon alpha 2B variants

Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

Combination of lenalidomide and polypeptide construct, and uses thereof

Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

Growing community of inventors

Macquarie Park, Australia

Collette Behrens